RLYB vs. LPTX, MGTA, CTMX, CRDF, EBS, FHTX, ACRV, QURE, XBIT, and PYXS
Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Leap Therapeutics (LPTX), Magenta Therapeutics (MGTA), CytomX Therapeutics (CTMX), Cardiff Oncology (CRDF), Emergent BioSolutions (EBS), Foghorn Therapeutics (FHTX), Acrivon Therapeutics (ACRV), uniQure (QURE), XBiotech (XBIT), and Pyxis Oncology (PYXS). These companies are all part of the "medical" sector.
Rallybio (NASDAQ:RLYB) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking.
Rallybio currently has a consensus target price of $12.20, indicating a potential upside of 630.54%. Leap Therapeutics has a consensus target price of $11.00, indicating a potential upside of 352.67%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than Leap Therapeutics.
Rallybio has higher earnings, but lower revenue than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
90.3% of Rallybio shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 7.4% of Rallybio shares are owned by insiders. Comparatively, 11.3% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Rallybio's return on equity of -66.59% beat Leap Therapeutics' return on equity.
In the previous week, Rallybio had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 2 mentions for Rallybio and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.19 beat Rallybio's score of 0.93 indicating that Leap Therapeutics is being referred to more favorably in the news media.
Rallybio has a beta of -1.63, meaning that its share price is 263% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
Leap Therapeutics received 257 more outperform votes than Rallybio when rated by MarketBeat users. However, 73.33% of users gave Rallybio an outperform vote while only 68.72% of users gave Leap Therapeutics an outperform vote.
Summary
Rallybio beats Leap Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Rallybio News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rallybio Competitors List
Related Companies and Tools
